Renalytix - ROA 2020-2024 | RNLXY
Current and historical return on assets (ROA) values for Renalytix - (RNLXY) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.
| Renalytix - ROA - Return on Assets Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Total Assets | Return on Assets |
| 2024-09-30 | $-0.03B | $0.01B | -339.39% |
| 2024-06-30 | $-0.03B | $0.01B | -275.00% |
| 2024-03-31 | $-0.04B | $0.01B | -208.45% |
| 2023-12-31 | $-0.04B | $0.01B | -160.78% |
| 2023-09-30 | $-0.04B | $0.02B | -140.98% |
| 2023-06-30 | $-0.05B | $0.03B | -127.66% |
| 2023-03-31 | $-0.04B | $0.04B | -97.50% |
| 2022-12-31 | $-0.04B | $0.03B | -102.44% |
| 2022-09-30 | $-0.05B | $0.04B | -100.53% |
| 2022-06-30 | $-0.05B | $0.05B | -83.72% |
| 2022-03-31 | $-0.05B | $0.04B | -81.97% |
| 2021-12-31 | $-0.04B | $0.05B | -61.75% |
| 2021-09-30 | $-0.04B | $0.07B | -47.20% |
| 2021-06-30 | $-0.04B | $0.08B | -40.46% |
| 2021-03-31 | $-0.03B | $0.09B | -38.89% |
| 2020-12-31 | $-0.02B | $0.09B | -39.41% |
| 2020-09-30 | $-0.02B | $0.09B | -57.14% |
| 2020-06-30 | $-0.01B | $0.02B | -190.48% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Information Systems | $0.038B | $0.003B |
| Renalytix plc is an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care. Renalytix plc, formerly known as RENALYTIX AI, is based in NEW YORK. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Veeva Systems (VEEV) | United States | $47.812B | 58.34 |
| Tempus AI (TEM) | United States | $11.803B | 0.00 |
| Doximity (DOCS) | United States | $9.361B | 38.54 |
| Hims & Hers Health (HIMS) | United States | $8.207B | 66.76 |
| IRhythm Technologies (IRTC) | United States | $5.429B | 0.00 |
| Hinge Health (HNGE) | United States | $3.287B | 0.00 |
| Privia Health (PRVA) | United States | $2.921B | 182.69 |
| Heartflow (HTFL) | United States | $2.635B | 0.00 |
| Inspire Medical Systems (INSP) | United States | $2.522B | 41.72 |
| 10x Genomics (TXG) | United States | $2.035B | 0.00 |
| Enovis (ENOV) | United States | $1.765B | 9.27 |
| Omnicell (OMCL) | United States | $1.596B | 32.62 |
| Azenta (AZTA) | United States | $1.370B | 59.76 |
| Phreesia (PHR) | United States | $1.350B | 0.00 |
| Clover Health Investments (CLOV) | United States | $1.276B | 0.00 |
| Schrodinger (SDGR) | United States | $1.267B | 0.00 |
| Fulgent Genetics (FLGT) | United States | $0.915B | 0.00 |
| Claritev (CTEV) | United States | $0.730B | 0.00 |
| Talkspace (TALK) | United States | $0.535B | 107.67 |
| Veradigm (MDRX) | United States | $0.534B | 0.00 |
| Butterfly Network (BFLY) | United States | $0.523B | 0.00 |
| Evolent Health (EVH) | United States | $0.464B | 0.00 |
| Standard BioTools (LAB) | United States | $0.461B | 0.00 |
| Zepp Health (ZEPP) | Netherlands | $0.365B | 0.00 |
| Carlsmed (CARL) | United States | $0.338B | 0.00 |
| TruBridge (TBRG) | United States | $0.306B | 14.08 |
| SOPHiA GENETICS SA (SOPH) | Switzerland | $0.296B | 0.00 |
| CapsoVision (CV) | United States | $0.265B | 0.00 |
| Insight Molecular Diagnostics (IMDX) | United States | $0.225B | 0.00 |
| KORU Medical Systems (KRMD) | United States | $0.202B | 0.00 |
| MDxHealth SA (MDXH) | Belgium | $0.188B | 0.00 |
| Nyxoah SA (NYXH) | Belgium | $0.181B | 0.00 |
| Health Catalyst (HCAT) | United States | $0.166B | 0.00 |
| CareCloud (CCLD) | United States | $0.135B | 7.40 |
| EUDA Health Holdings (EUDA) | Singapore | $0.113B | 0.00 |
| Outset Medical (OM) | United States | $0.089B | 0.00 |
| NetraMark Holdings (AINMF) | Canada | $0.076B | 0.00 |
| Pulmonx (LUNG) | United States | $0.066B | 0.00 |
| American Well (AMWL) | United States | $0.065B | 0.00 |
| HeartBeam (BEAT) | United States | $0.054B | 0.00 |
| P3 Health Partners (PIII) | United States | $0.050B | 0.00 |
| Evaxion - (EVAX) | Denmark | $0.036B | 0.00 |
| 111 (YI) | China | $0.035B | 0.00 |
| Precipio (PRPO) | United States | $0.032B | 0.00 |
| Predictive Oncology (POAI) | United States | $0.027B | 0.00 |
| Lunai Bioworks (LNAI) | United States | $0.024B | 0.00 |
| Zhongchao (ZCMD) | China | $0.017B | 0.00 |
| Healthcare Triangle (HCTI) | United States | $0.013B | 0.00 |
| Bullfrog AI Holdings (BFRG) | United States | $0.010B | 0.00 |
| Movano (MOVE) | United States | $0.009B | 0.00 |
| HeartSciences (HSCS) | United States | $0.008B | 0.00 |
| PROFUSA (PFSA) | United States | $0.008B | 0.00 |
| Strata Skin Sciences (SSKN) | United States | $0.008B | 0.00 |
| Tivic Health Systems (TIVC) | United States | $0.002B | 0.00 |
| Mobile-health Network Solutions (MNDR) | Singapore | $0.002B | 0.00 |
| MSP Recovery (MSPR) | United States | $0.001B | 0.00 |